

WHAT IS CLAIMED:

- 1 1. A method for enhancing fibroblast
2 migration at a wound site comprising:
3 contacting the wound site with fibrinogen
4 prepared by a process which comprises precipitating
5 plasma with glycine.
- 1 2. A method according to claim 1, wherein the
2 precipitating is carried out at temperatures below room
3 temperature.
- 1 3. A method according to claim 1, wherein the
2 precipitating is carried out at temperatures between
3 about 2 °C and about 7 °C.
- 1 4. A method according to claim 1, wherein the
2 precipitating is carried out by adding glycine to plasma
3 to produce a mixture, wherein the glycine is added in a
4 concentration to produce glycine in the mixture of from
5 about 1.0 to about 2.1 M.
- 1 5. A method according to claim 1, wherein
2 said contacting is carried out with fibrinogen prepared
3 by a process comprising:
4 precipitating plasma with glycine to produce a
5 precipitate and a supernatant;
6 dissolving the precipitate in a buffer to
7 produce a solution; and
8 precipitating the solution by adding glycine to
9 the solution.

1 6. A method according to claim 5, wherein the
2 buffer has a pH of from about 6 to about 8.

1 7. A method according to claim 5, wherein the
2 plasma from which fibrinogen is precipitated has a volume
3 V and wherein the buffer has a volume of from about 0.3 V
4 to about 0.4 V.

1 8. A method according to claim 5, wherein the
2 plasma is precipitated by adding glycine to plasma to a
3 concentration of from about 1.0 to about 2.1 M and
4 wherein the solution is precipitated by adding glycine to
5 the solution to a concentration of from about 1.7 to
6 about 2.2 M.

1 9. A method according to claim 1, wherein
2 said contacting is carried out with fibrinogen prepared
3 by a process comprising:
4 precipitating plasma with glycine to produce a
5 first precipitate and a first supernatant;
6 dissolving the first precipitate in a buffer to
7 produce a first solution;
8 precipitating the first solution by adding
9 glycine to the first solution to produce a second
10 precipitate and a second supernatant;
11 dissolving the second precipitate in a buffer
12 to produce a second solution; and
13 precipitating the second solution by adding
14 ammonium sulfate to the second solution to produce a
15 third precipitate and a third supernatant.

00500512-020000

6 precipitating the supernatant by adding glycine
7 to the supernatant.

```
11         precipitating the first solution by adding
12 glycine to the first solution.
```

precipitating plasma with glycine to produce a
first precipitate and a first supernatant;

7
8
9
10
11
12
13
14

1 15. A method according to claim 9, wherein the
2 third supernatant comprises a lipid rich layer.

1 16. A method according to claim 15, wherein the
2 third supernatant is further treated to produce a lipid
3 rich component.

1
2
3
1
2

Page 3

3 contacting the wound site with a fibrinogen
4 preparation, wherein the fibrinogen preparation includes a
5 lipid rich component.

1 19. A method according to claim 18 wherein the
2 fibrinogen preparation further comprises fibrinogen
3 prepared by a process which comprises precipitating plasma
4 with glycine.

1 20. A method according to claim 19 wherein the
2 fibrinogen preparation further comprises a growth factor,
3 an extracellular matrix material, or mixtures thereof.

1 21. A method according to claim 19 wherein the
2 precipitating is carried out by a process which comprises:
3 adding glycine to plasma to produce a
4 precipitate and a supernatant;
5 dissolving the precipitate in a buffer to
6 produce a solution; and
7 precipitating the solution by adding glycine to
8 the solution.

1 22. A method according to claim 19 wherein the
2 fibrinogen is prepared by a process comprising:
3 precipitating plasma with glycine to produce a
4 first precipitate and a first supernatant;
5 dissolving the first precipitate in a buffer to
6 produce a first solution;
7 precipitating the first solution by adding
8 glycine to the first solution to produce a second
9 precipitate and a second supernatant;
10 dissolving the second precipitate in a buffer to
11 produce a second solution; and

00500542 020900

1 23. A method according to claim 22 wherein the
2 third supernatant comprises a lipid rich layer.

1 25. A method according to claim 24 wherein the
2 third supernatant is precipitated to produce the lipid
3 rich component.

1 27. A composition according to claim 26 wherein
2 the fibrinogen has a purity of above 95%.

1 29. A composition according to claim 26 wherein
2 the fibrinogen is prepared by a process which comprises
3 precipitating plasma with glycine.

1 30. A composition according to claim 29 wherein
2 the fibrinogen is prepared by a process which comprises:
3 precipitating plasma with glycine to produce a
4 first precipitate and a first supernatant;

5 dissolving the first precipitate in a buffer to
6 produce a first solution;
7 precipitating the first solution by adding
8 glycine to the first solution to produce a second
9 precipitate and a second supernatant;
10 dissolving the second precipitate in a buffer to
11 produce a second solution; and
12 precipitating the second solution by adding
13 ammonium sulfate to the second solution to produce a third
14 precipitate and a third supernatant.

1 31. A composition according to claim 26 wherein
2 the lipid rich component is prepared by a process which
3 comprises precipitating plasma with glycine.

1 32. A composition according to claim 31 wherein
2 the lipid rich component is prepared by a process which
3 comprises:

4 precipitating plasma with glycine to produce a
5 first precipitate and a first supernatant;
6 dissolving the first precipitate in a buffer to
7 produce a first solution;
8 precipitating the first solution by adding
9 glycine to the first solution to produce a second
10 precipitate and a second supernatant;
11 dissolving the second precipitate in a buffer to
12 produce a second solution;
13 precipitating the second solution by adding
14 ammonium sulfate to the second solution to produce a third
15 precipitate and a third supernatant; and
16 precipitating the third supernatant to produce
17 the lipid rich component.

006020-020900